Concepedia

Savithri Ramurthy

SR

Statistics

Publications

22

Citations

731

H-Index

17

Active since

1994

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Genomics Institute of the Novartis Research Foundation

University of Notre Dame

Gilead Sciences (United States)

Savithri Ramurthy is an author at Novartis (Switzerland) specializing in drug discovery, medicinal chemistry, and pharmacology.

ORCID

Publications per year

1994–2024

22

Publications

22

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Rama Jain, Michelle Mathur, Jiong Lan et al. · Journal of Medicinal Chemistry · 2015 · 83 citations · Full text

, , +13

Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors

Savithri Ramurthy, Sharadha Subramanian, Mina Aikawa et al. · Journal of Medicinal Chemistry · 2008 · 76 citations · Full text

, , +13

4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors

Zhi‐Jie Ni, Paul A. Barsanti, Nathan Brammeier et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 71 citations · Full text

, , +7

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Teresa E. Williams, Sharadha Subramanian, Joelle Verhagen et al. · ACS Medicinal Chemistry Letters · 2015 · 54 citations · Full text

, , +17

Design and Discovery of <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

Gisele Nishiguchi, Alice Rico, Huw R. Tanner et al. · Journal of Medicinal Chemistry · 2017 · 44 citations · Full text

, , +15

1–5 of 22